Default company panoramic image
New 20logo

ViroCarb Inc.

A new approach for prevention and treatment of HIV/AIDS

  • Stage Product In Development
  • Industry Biotechnology
  • Location Toronto, ON, Canada
  • Currency CAD
  • Founded April 2011
  • Employees 4
  • Incorporation Type Other
  • Website

Company Summary

ViroCarb’s business model is focused on patent protection of a critical segment of the HIV drug resistance scientific area and bringing a platform of molecules to an exit early in the clinical development stage. Our drug will be in a strong position to dominate the increasing multibillion dollar HIV drug resistance market and the newly emerging HIV prophylaxis drug market. We intent to develop an early clinical stage drug candidate within 3 years


  • Default avatar
    Dr. Mario Huesca
    Co-founder & President/Chief Operating Officer

    Dr. Huesca has more than 11 years’ experience in the discovery and development of novel therapies for cancer and infectious disease. He led the discovery and development of several drug candidates currently in preclinical stage and in clinical trials in patients with advanced cancer. He obtained degrees in Pharmaceutical Chemistry and Pharmacology and a PhD in Molecular Genetics and Microbiology from the University of Toronto

  • Default avatar
    Dr. Clifford Lingwood
    Co-founder& Chief Scientific Officer

    Dr. Lingwood is Sr. Scientist at the Hospital for Sick Children and world leader on glycosphingolipids (GSL) receptor functions. He was the first to develop GSL mimetics with HIV entry inhibitory activity. Together with Dr. Donald Branch, a company cofounder, he identified the GSL Gb3 (Pk blood group antigen) as a natural resistance factor against HIV infection. He has published 184 original scientific papers and is the holder of 20 patents

  • Default avatar
    Dr. Donald Branch
    Co-founder & Scientific Director

    Dr. Branch is Professor of Medicine (Hematology) and Laboratory Medicine and Pathobiology, University of Toronto, expert in pathogenesis of HIV infection, signal transduction and design of alternative therapies for HIV/AIDS. He has published more than 100 original research papers and has received awards of distinction from the American Society of Hematology, American Association of Blood Banks and the Canadian Society for Transfusion Medicine


  • Default avatar
    Jay A. Lefton (Corporate and Securities Law, Borden Ladner Gervais LLP)
    Default avatar
    Jeffrey Hunter, CA (Forbes Andersen LLP)

Previous Investors

  • Default avatar
    Private investors
    Default avatar
    Mario Huesca